Showing 81-90 of 9823 results for "".
Hair Care Trends and Treatment Advances
https://practicaldermatology.com/conferences/aad-summer-2021/hair-care-trends-and-treatment-advances/19970/Ronda S. Farah, MD shares highlights from the session she and co-panelists presented on technological advancements in the management of scalp disease. They cover the role of artificial intelligence in monitoring patients, hair cosmetic trends, lasers and platelet rich plasma in 2021, novel technologBest Practices: Allan Wirtzer, MD on Leadership
https://practicaldermatology.com/topics/practice-management/best-practices-allan-wirtzer-md-on-leadership/18592/Sometimes the most important role of a physician is leader. Whether in your practice or for your specialty overall, doctors must lead the charge forward. In this edition of Best Practices, host Joel L. Cohen, MD talks to Allan S. Wirtzer, MD about issues affecting medicine, including coding, and theValeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicL'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-l-oreal-nabs-cerave-smart-beauty-tools-skin-cancer-knowledge-lacking/18703/Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell itsUpdates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,Keloids: To Cut or Not to Cut
https://practicaldermatology.com/topics/skin-cancer-photoprotection/keloids-to-cut-or-not-to-cut/19987/When treating keloids, ask patients what they want to achieve. Are they hoping to decrease itch or pain? Do they want to flatten or soften the appearance of a keloid? Hilary Baldwin, MD reviews her approach to deciding whether to remove a keloid surgically as well as other treatment options. Plus, sDerm Insider: Navigating Office Politics
https://practicaldermatology.com/topics/practice-management/derm-insider-navigating-office-politics/18993/In this edition of Derm Insider, host Neal Bhatia, MD speaks with practice management experts about the complex inner workings of an office environment, as well as the role of physicians in managing precarious situations regarding employees. Offering advice for maneuvering these situations, guests SLight & Bright: A new treatment to illuminate your practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/light-bright-a-new-treatment-to-illuminate-your-practice/19746/Join Matthew Mahlberg, MD as he introduces the new Light & Bright treatment. Using the patented Ellipse IPL and Frax 1550 technologies on the Nordlys system, the Light & Bright treatment reduces pigmentation & redness and improves textural irregularities. Hear the results of a clinical sDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sActinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be s